Teacher Retirement System of Texas Has $327,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Teacher Retirement System of Texas increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,317 shares of the company’s stock after acquiring an additional 10,355 shares during the quarter. Teacher Retirement System of Texas’ holdings in Amneal Pharmaceuticals were worth $327,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Franklin Resources Inc. increased its stake in Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after purchasing an additional 4,178 shares in the last quarter. Arizona State Retirement System increased its position in Amneal Pharmaceuticals by 13.6% in the 4th quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock valued at $320,000 after buying an additional 4,851 shares in the last quarter. Globeflex Capital L P increased its position in Amneal Pharmaceuticals by 3.8% in the 4th quarter. Globeflex Capital L P now owns 144,439 shares of the company’s stock valued at $1,144,000 after buying an additional 5,245 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock worth $366,000 after buying an additional 5,523 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Amneal Pharmaceuticals by 1.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 555,655 shares of the company’s stock worth $4,401,000 after acquiring an additional 6,680 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ:AMRX opened at $8.23 on Wednesday. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -12.10 and a beta of 1.05. The business’s 50 day moving average is $8.41 and its 200 day moving average is $8.37. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.18 and a 12-month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the previous year, the company earned $0.14 EPS. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the sale, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,240,000 shares of company stock valued at $43,754,000. Corporate insiders own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

AMRX has been the subject of several recent research reports. Barclays boosted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.